The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling

Melissa N. van Tok, Songqing Na, Christopher R. Lao, Marina Alvi, Desirée Pots, Marleen G.H. van de Sande, Joel D. Taurog, Jonathon D. Sedgwick, Dominique L. Baeten, Leonie M. van Duivenvoorde

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

IL-17A is a central driver of spondyloarthritis (SpA), its production was originally proposed to be IL-23 dependent. Emerging preclinical and clinical evidence suggests, however, that IL-17A and IL-23 have a partially overlapping but distinct biology. We aimed to assess the extent to which IL-17A-driven pathology is IL-23 dependent in experimental SpA. Experimental SpA was induced in HLA-B27/Huβ2m transgenic rats, followed by prophylactic or therapeutic treatment with an anti-IL23R antibody or vehicle control. Spondylitis and arthritis were scored clinically and hind limb swelling was measured. Draining lymph node cytokine expression levels were analyzed directly ex vivo, and IL-17A protein was measured upon restimulation with PMA/ionomycin. Prophylactic treatment with anti-IL23R completely protected against the development of both spondylitis and arthritis, while vehicle-treated controls did develop spondylitis and arthritis. In a therapeutic study, anti-IL23R treatment failed to reduce the incidence or decrease the severity of experimental SpA. Mechanistically, expression of downstream effector cytokines, including IL-17A and IL-22, was significantly suppressed in anti-IL23R versus vehicle-treated rats in the prophylactic experiments. Accordingly, the production of IL-17A upon restimulation was reduced. In contrast, there was no difference in IL-17A and IL-22 expression after therapeutic anti-IL23R treatment. Targeting the IL-23 axis during the initiation phase of experimental SpA-but not in established disease-inhibits IL-17A expression and suppresses disease, suggesting the existence of IL-23-independent IL-17A production. Whether IL-17A can be produced independent of IL-23 in human SpA remains to be established.

Original languageEnglish (US)
Article number1550
JournalFrontiers in Immunology
Volume9
Issue numberJUL
DOIs
StatePublished - Jul 9 2018

Fingerprint

Interleukin-23
Interleukin-17
Spondylitis
Arthritis
Cytokines
Transgenic Rats
HLA-B27 Antigen
Ionomycin
Anti-Idiotypic Antibodies
Therapeutics
Extremities
Lymph Nodes
Pathology

Keywords

  • Animal models
  • Experimental spondyloarthritis
  • HLA-B27 tg rats
  • IL-17A
  • IL-23 signaling
  • IL-23R
  • Spondyloarthritis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

van Tok, M. N., Na, S., Lao, C. R., Alvi, M., Pots, D., van de Sande, M. G. H., ... van Duivenvoorde, L. M. (2018). The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling. Frontiers in Immunology, 9(JUL), [1550]. https://doi.org/10.3389/fimmu.2018.01550

The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling. / van Tok, Melissa N.; Na, Songqing; Lao, Christopher R.; Alvi, Marina; Pots, Desirée; van de Sande, Marleen G.H.; Taurog, Joel D.; Sedgwick, Jonathon D.; Baeten, Dominique L.; van Duivenvoorde, Leonie M.

In: Frontiers in Immunology, Vol. 9, No. JUL, 1550, 09.07.2018.

Research output: Contribution to journalArticle

van Tok, MN, Na, S, Lao, CR, Alvi, M, Pots, D, van de Sande, MGH, Taurog, JD, Sedgwick, JD, Baeten, DL & van Duivenvoorde, LM 2018, 'The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling', Frontiers in Immunology, vol. 9, no. JUL, 1550. https://doi.org/10.3389/fimmu.2018.01550
van Tok, Melissa N. ; Na, Songqing ; Lao, Christopher R. ; Alvi, Marina ; Pots, Desirée ; van de Sande, Marleen G.H. ; Taurog, Joel D. ; Sedgwick, Jonathon D. ; Baeten, Dominique L. ; van Duivenvoorde, Leonie M. / The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling. In: Frontiers in Immunology. 2018 ; Vol. 9, No. JUL.
@article{3b82a853a1294727959b7ad8b146029a,
title = "The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling",
abstract = "IL-17A is a central driver of spondyloarthritis (SpA), its production was originally proposed to be IL-23 dependent. Emerging preclinical and clinical evidence suggests, however, that IL-17A and IL-23 have a partially overlapping but distinct biology. We aimed to assess the extent to which IL-17A-driven pathology is IL-23 dependent in experimental SpA. Experimental SpA was induced in HLA-B27/Huβ2m transgenic rats, followed by prophylactic or therapeutic treatment with an anti-IL23R antibody or vehicle control. Spondylitis and arthritis were scored clinically and hind limb swelling was measured. Draining lymph node cytokine expression levels were analyzed directly ex vivo, and IL-17A protein was measured upon restimulation with PMA/ionomycin. Prophylactic treatment with anti-IL23R completely protected against the development of both spondylitis and arthritis, while vehicle-treated controls did develop spondylitis and arthritis. In a therapeutic study, anti-IL23R treatment failed to reduce the incidence or decrease the severity of experimental SpA. Mechanistically, expression of downstream effector cytokines, including IL-17A and IL-22, was significantly suppressed in anti-IL23R versus vehicle-treated rats in the prophylactic experiments. Accordingly, the production of IL-17A upon restimulation was reduced. In contrast, there was no difference in IL-17A and IL-22 expression after therapeutic anti-IL23R treatment. Targeting the IL-23 axis during the initiation phase of experimental SpA-but not in established disease-inhibits IL-17A expression and suppresses disease, suggesting the existence of IL-23-independent IL-17A production. Whether IL-17A can be produced independent of IL-23 in human SpA remains to be established.",
keywords = "Animal models, Experimental spondyloarthritis, HLA-B27 tg rats, IL-17A, IL-23 signaling, IL-23R, Spondyloarthritis",
author = "{van Tok}, {Melissa N.} and Songqing Na and Lao, {Christopher R.} and Marina Alvi and Desir{\'e}e Pots and {van de Sande}, {Marleen G.H.} and Taurog, {Joel D.} and Sedgwick, {Jonathon D.} and Baeten, {Dominique L.} and {van Duivenvoorde}, {Leonie M.}",
year = "2018",
month = "7",
day = "9",
doi = "10.3389/fimmu.2018.01550",
language = "English (US)",
volume = "9",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "JUL",

}

TY - JOUR

T1 - The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling

AU - van Tok, Melissa N.

AU - Na, Songqing

AU - Lao, Christopher R.

AU - Alvi, Marina

AU - Pots, Desirée

AU - van de Sande, Marleen G.H.

AU - Taurog, Joel D.

AU - Sedgwick, Jonathon D.

AU - Baeten, Dominique L.

AU - van Duivenvoorde, Leonie M.

PY - 2018/7/9

Y1 - 2018/7/9

N2 - IL-17A is a central driver of spondyloarthritis (SpA), its production was originally proposed to be IL-23 dependent. Emerging preclinical and clinical evidence suggests, however, that IL-17A and IL-23 have a partially overlapping but distinct biology. We aimed to assess the extent to which IL-17A-driven pathology is IL-23 dependent in experimental SpA. Experimental SpA was induced in HLA-B27/Huβ2m transgenic rats, followed by prophylactic or therapeutic treatment with an anti-IL23R antibody or vehicle control. Spondylitis and arthritis were scored clinically and hind limb swelling was measured. Draining lymph node cytokine expression levels were analyzed directly ex vivo, and IL-17A protein was measured upon restimulation with PMA/ionomycin. Prophylactic treatment with anti-IL23R completely protected against the development of both spondylitis and arthritis, while vehicle-treated controls did develop spondylitis and arthritis. In a therapeutic study, anti-IL23R treatment failed to reduce the incidence or decrease the severity of experimental SpA. Mechanistically, expression of downstream effector cytokines, including IL-17A and IL-22, was significantly suppressed in anti-IL23R versus vehicle-treated rats in the prophylactic experiments. Accordingly, the production of IL-17A upon restimulation was reduced. In contrast, there was no difference in IL-17A and IL-22 expression after therapeutic anti-IL23R treatment. Targeting the IL-23 axis during the initiation phase of experimental SpA-but not in established disease-inhibits IL-17A expression and suppresses disease, suggesting the existence of IL-23-independent IL-17A production. Whether IL-17A can be produced independent of IL-23 in human SpA remains to be established.

AB - IL-17A is a central driver of spondyloarthritis (SpA), its production was originally proposed to be IL-23 dependent. Emerging preclinical and clinical evidence suggests, however, that IL-17A and IL-23 have a partially overlapping but distinct biology. We aimed to assess the extent to which IL-17A-driven pathology is IL-23 dependent in experimental SpA. Experimental SpA was induced in HLA-B27/Huβ2m transgenic rats, followed by prophylactic or therapeutic treatment with an anti-IL23R antibody or vehicle control. Spondylitis and arthritis were scored clinically and hind limb swelling was measured. Draining lymph node cytokine expression levels were analyzed directly ex vivo, and IL-17A protein was measured upon restimulation with PMA/ionomycin. Prophylactic treatment with anti-IL23R completely protected against the development of both spondylitis and arthritis, while vehicle-treated controls did develop spondylitis and arthritis. In a therapeutic study, anti-IL23R treatment failed to reduce the incidence or decrease the severity of experimental SpA. Mechanistically, expression of downstream effector cytokines, including IL-17A and IL-22, was significantly suppressed in anti-IL23R versus vehicle-treated rats in the prophylactic experiments. Accordingly, the production of IL-17A upon restimulation was reduced. In contrast, there was no difference in IL-17A and IL-22 expression after therapeutic anti-IL23R treatment. Targeting the IL-23 axis during the initiation phase of experimental SpA-but not in established disease-inhibits IL-17A expression and suppresses disease, suggesting the existence of IL-23-independent IL-17A production. Whether IL-17A can be produced independent of IL-23 in human SpA remains to be established.

KW - Animal models

KW - Experimental spondyloarthritis

KW - HLA-B27 tg rats

KW - IL-17A

KW - IL-23 signaling

KW - IL-23R

KW - Spondyloarthritis

UR - http://www.scopus.com/inward/record.url?scp=85049617505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049617505&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2018.01550

DO - 10.3389/fimmu.2018.01550

M3 - Article

C2 - 30038617

AN - SCOPUS:85049617505

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - JUL

M1 - 1550

ER -